Contents
Download PDF
pdf Download XML
156 Views
81 Downloads
Share this article
Research Article | Volume 2 Issue 1 (, 2012) | Pages 21 - 30
The Antiplatelet Journey Thus Far: Focus On New Oral P2Y12 Inhibitors
Under a Creative Commons license
Open Access
Published
March 23, 2012
Abstract
Platelets are pivotal in the pathophysiology of acute coronary syndromes; the leading cause of death worldwide. The use of antiplatelet agents in the treatment of acute coronary syndromes has reduced morbidity and mortality substantially. Thus, aspirin has been a cornerstone in the treatment of acute coronary syndromes for years. However, during the last decade the P2Y12 inhibitor clopidogrel has accompanied aspirin to further improve clinical outcomes. P2Y12 inhibitors are antiplatelet agents preventing the binding of adenosine diphosphate to P2Y12 receptors on the platelet surface thus inhibiting platelet aggregation. Recently, the emergence of two new P2Y12 inhibitors, prasugrel and ticagrelor, has challenged the role of clopidogrel. Similar to clopidogrel, prasugrel is a prodrug that needs hepatic conversion to its active metabolite to provide irreversible P2Y12 inhibition. In contrast, ticagrelor is a direct-acting allosteric P2Y12 antagonist inhibiting the P2Y12 receptor reversibly. Both drugs provide a better pro- tection against cardiovascular outcomes than clopidogrel as evidenced by large clinical trials. This benefit might partly reflect the rapid onset of action and the pronounced antiplatelet effect of these drugs compared to clopidogrel. So far, no direct comparison of prasugrel and ticagrelor has been performed, but ongoing trials will provide data to clarify the clinical role of these drugs. The present review outlines the key milestones of the history of P2Y12 inhibitors and provides an up- to-date overview and comparison of the clinical applicability of these drugs.
Keywords
Recommended Articles
Case Report
Aortic Aneurysm with Dissection
Published: 12/08/2023
Download PDF
Research Article
“A study on the clinical profile of newly diagnosed cases of bronchogenic carcinoma in a tertiary care hospital”
Published: 16/09/2024
Download PDF
Chat on WhatsApp
Copyright © EJCM Publisher. All Rights Reserved.